# Ipamorelin vs Sermorelin: What the Research Shows

> Ipamorelin vs Sermorelin compared by receptor class, mechanism, half-life, selectivity, and research context. Two distinct GH-axis entry points, studied across different experimental models.

## Mechanism Differences: Ipamorelin vs Sermorelin

Sermorelin is a synthetic 29-amino-acid fragment of endogenous GHRH. It binds the GHRH receptor (GHRH-R) via Gαs/adenylate cyclase/cAMP/PKA cascade [14]. GHRH-R activation increases the proportion of somatotrophs primed for GH secretion; it does not directly trigger calcium-mediated exocytosis.

Ipamorelin binds GHS-R1a via the Gq/11 pathway, mobilizing intracellular calcium to drive acute GH vesicle exocytosis and simultaneously suppressing hypothalamic somatostatin [1]. The two receptor families are distinct, located on the same somatotroph cell but coupled to different G-proteins and cascades.

## Half-Life and Pharmacokinetics: Ipamorelin vs Sermorelin

Sermorelin: plasma half-life 11–12 minutes IV or SC [14]. Requires multiple daily injections for sustained GH-axis stimulation.

Ipamorelin: plasma half-life approximately 2 hours [2]. Each SC injection produces one GH pulse peaking at 15–40 minutes with return to baseline at approximately 3 hours.

## Safety Profiles: Ipamorelin vs Sermorelin in Research

Sermorelin: no significant elevation of prolactin, insulin, cortisol, glucose, or thyroid hormones at studied human doses [14]. Ipamorelin: no significant elevation of ACTH, cortisol, prolactin, FSH, or LH at doses up to more than 200-fold the GH-releasing ED₅₀ [1]. Both avoid the cortisol/prolactin elevation seen with hexarelin, GHRP-6, and GHRP-2.

## Co-Administration of Sermorelin and Ipamorelin

Some preclinical models study GHRH + GHRP co-administration to assess additive GH-pulse effects. Sermorelin's 11–12 minute half-life and ipamorelin's ~2-hour half-life create different priming dynamics than the longer-acting CJC-1295 combination [10, 14]. No approved co-administration protocol exists.

## Is Ipamorelin Better Than Sermorelin?

No head-to-head controlled trial comparing ipamorelin and sermorelin on a shared outcome measure appears in the published literature. The Sinha 2020 review identified both compounds in the GHS body-composition literature without ranking them [12]. "Better" is not a term the published record supports for this comparison.

## References

[1] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.
[2] Johansen PB, et al. Pharmacokinetic evaluation of ipamorelin. Xenobiotica. 1998;28(12):1235-1248.
[10] Teichman SL, et al. Prolonged Stimulation of GH and IGF-I by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.
[12] Sinha DK, et al. Beyond the androgen receptor: GH secretagogues in body composition management. Transl Androl Urol. 2020;9(Suppl 2):S149-S159.
[14] Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25-37.

---

A grid-indexed literature digest on Ipamorelin — nineteen primary findings, clean GH pulses, and no commercial position on any of them.